CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo

Area of Science:

• Immunology
• Cellular Biology
• Vaccinology

Background:

• T cell activation requires T cell receptor (TCR) ligation and co-stimulation via B7 ligands (e.g., CD86) engaging CD28/CTLA-4.
• Previous work showed CD86 cDNA co-administration with DNA encoding HIV-1 antigens enhances antigen-specific cytotoxic T lymphocyte (CTL) responses.

Purpose of the Study:

• To determine if bone marrow-derived antigen-presenting cells (APCs) or muscle cells mediate the CTL response enhancement observed with CD86 co-administration.
• To elucidate the role of CD86 in CTL induction in vivo.

Main Methods:

• Utilized bone marrow chimeras capable of generating functional viral-specific CTLs against vaccinia virus.
• Analyzed CTL induction in vaccinated chimeras by assessing CD86, antigen, and MHC class I expression.
• Evaluated CTL detection via in vitro restimulation, direct CTL activity, IFN-gamma production, and T cell tissue invasion.

Main Results:

• CD86, antigen, and MHC class I co-expression were necessary for detectable CTL induction.
• Observed enhanced antigen-specific CTL responses, including increased IFN-gamma production and significant T cell tissue invasion.
• Demonstrated that non-bone marrow-derived cells can prime CTLs in the presence of CD86.

Conclusions:

• CD86 plays a critical role in promoting CTL induction in vivo.
• Non-bone marrow-derived cells can act as effective APCs for CTL priming when CD86 is present.
• These findings challenge the traditional view of APC function in T cell immunity.